Increased Affordability and Patient Access

Since Hospira launched its biosimilars, prices have decreased and patient access has increased.

In Europe and Australia, biosimilar treatments offer cost savings to healthcare systems of approximately 25 percent to 30 percent.¹ In the United States, newer biologic treatments can cost $100,000 or more per patient, per year.² A price decrease in the United States similar to the one experienced in Europe would benefit patients and payers alike.

A number of studies predict that successful adoption of biosimilars in the United States could result in significant savings for U.S. patients and the U.S. healthcare system driven by increased competition. A 2013 study by accounting firm Grant Thornton found that biosimilars hold the potential to save $20 billion annually in the United States.³

Market Penetration of Biosimilars and U.S. Market Formation

With the continued safe and effective record of biosimilars in European Union clinical practice, use in many markets is widespread and growing rapidly. Throughout the European Union, biosimilar versions of GCSF had gained almost 41 percent of the total daily GCSF market by the end of 2012, up from 30 percent at the start of the year.⁴ During the same period, EPO biosimilars had grown their market share to 19 percent of the European short-acting EPO market, up from 15 percent at the beginning of 2012.⁵

"Biosimilars have come to stay in Europe, and we're very pleased with the progress we are seeing," Hospira's Moore said. "European and Australian physicians trust in the safety, efficacy and quality of biosimilars for their patients."

구글링 하다가 발견했습니다. 미국의 스피라라는 회사가 유럽에 바이오 시밀러 먼저 진출했는데 유럽과 호주에서는 바이오시밀러 치료가 25-30프로를 차지 한다고 합니다.

경쟁 상대가 나타나서 오지지날 약품의 가격을 내려서 실제 매출은 조금 떨어질수 있겠지만 엄청난 매출은 나올것은 확실합니다.

그리고 안티분들중에 바이오 시밀러 개나 소나 만들고 몇 년이후에 박터지게 싸워서 돈도 안된다고 하시지만 그렇게 않좋은 시장에 들어가고 싶어서 목메는 삼성, 엘지, 한화, 그 외에  세계의 유수의 엄청난  회사 등등 .